AlloVir, Inc.
NASDAQ Global SelectTotal Valuation
AlloVir, Inc. carries a market capitalization of 49.48M, placing it among publicly traded companies globally. Its enterprise value stands at -69.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 49.48M |
| Enterprise Value | -69.96M |
Share Statistics
AlloVir, Inc. currently has 5.04M shares outstanding.
| Shares Outstanding | 5.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.07 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | -0.71 |
| P/OCF Ratio | -0.71 |
Financial Position
AlloVir, Inc. maintains a current ratio of 22.63, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 22.63 |
| Quick Ratio | 22.58 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -38.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
AlloVir, Inc.'s stock has declined approximately -43.65307% over the past 52 weeks. The 50-day moving average sits at 9.73, while the 200-day moving average is 14.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | -43.65307% |
| 50-Day Moving Average | 9.73 |
| 200-Day Moving Average | 14.55 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -55.26M, while operating income came in at -55.26M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -55.26M |
| Pretax Income | -58.77M |
| Net Income | -58.77M |
| EBITDA | -55.26M |
| EBIT | -55.26M |
| Earnings Per Share (EPS) | -11.75 |
Balance Sheet
Total book value stands at -714.96M, with working capital of 113.31M providing operational flexibility.
| Cash & Cash Equivalents | 118.29M |
| Total Debt | N/A |
| Net Debt | -118.29M |
| Equity (Book Value) | -714.96M |
| Book Value Per Share | -142.90 |
| Working Capital | 113.31M |
Cash Flow
AlloVir, Inc. produced -67.70M in operating cash flow over the past twelve months.
| Operating Cash Flow | -67.70M |
| Capital Expenditures | N/A |
| Free Cash Flow | -67.70M |
| FCF Per Share | -13.53 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -140.09 |
Stock Splits
AlloVir, Inc.'s most recent stock split took place on January 16, 2025 with a 23:1 split ratio.
| Last Split Date | 1/16/2025 |
| Split Ratio | 23:1 |
Scores
AlloVir, Inc. posts an Altman Z-Score of -3.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.30 |